Sonnet BioTherapeutics Stock Quote SONN - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.9439

Bid

0.9103

Ask

1.02

Volume

37,295

0.927 Day's Range 1.01

0.6239 52 Week Range 3.10

Market Cap

4.911M

Previous Close

1.00

Open

1.01

Last Trade

0.93

Last Trade Time

Financial Volume

$ 35,579

VWAP

0.953982

Average Volume (3m)

137,390

Shares Outstanding

5,202,505

Dividend Yield

PE Ratio

-0.26

Earnings Per Share (EPS)

-3.62

Revenue

148k

Net Profit

-18.83M

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more

Sector

Pharmaceutical Preparations

Industry

Management Consulting Svcs

Website

www.sonnetbio.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

Sonnet BioTherapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SONN. The last closing price for Sonnet BioTherapeutics was $1. Over the last year, Sonnet BioTherapeutics shares have traded in a share price range of $ 0.6239 to $ 3.10.

Sonnet BioTherapeutics currently has 5,202,505 shares outstanding. The market capitalization of Sonnet BioTherapeutics is $5.20 million. Sonnet BioTherapeutics has a price to earnings ratio (PE ratio) of -0.26.

Form 8-K - Current report

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative Immuno Oncology...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.1127	13.5587102984	0.8312	1.0896	0.83	107458	0.98287639	CS
4	0.1839	24.1973684211	0.76	1.0896	0.7001	74222	0.8881138	CS
12	0.0015	0.159168081494	0.9424	1.0896	0.6239	137390	0.80066392	CS
26	-1.2061	-56.0976744186	2.15	2.23	0.6239	82593	0.95433217	CS
52	-2.1561	-69.5516129032	3.1	3.1	0.6239	86162	1.3848982	CS
156	-181.0841	-99.4814534028	182.028	224.84	0.6239	2071190	87.94361612	CS
260	-1914.8161	-99.9507297365	1915.76	4989.6	0.6239	2383844	328.52901415	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
KAVLKaival Brands Innovations Group Inc	$ 1.33 (129.71%)	182.45M
LASELaser Photonics Corporation	$ 18.8671 (81.24%)	13.54M
TGLTreasure Global Inc	$ 1.18 (73.45%)	139.93M
NVVENuvve Holding Corporation	$ 6.68 (70.41%)	31.34M
UXINUxin Ltd	$ 2.42 (52.68%)	18.24M
ELABElevai Labs Inc	$ 0.10545 (-62.34%)	23.66M
ADTXAditxt Inc	$ 0.262 (-31.52%)	3.17M
FRGTFreight Technologies Inc	$ 0.081 (-28.82%)	26.36M
ANEBAnebulo Pharmaceuticals Inc	$ 2.23 (-27.60%)	113.78k
STSSSharps Technology Inc	$ 0.1722 (-27.06%)	2.27M
XPONExpion360 Inc	$ 0.1144 (34.91%)	432.17M
NVDANVIDIA Corporation	$ 116.26 (0.22%)	206.23M
INTCIntel Corporation	$ 22.56 (3.30%)	184.44M
KAVLKaival Brands Innovations Group Inc	$ 1.33 (129.71%)	182.46M
TGLTreasure Global Inc	$ 1.18 (73.45%)	139.95M